• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多价阳离子和聚阳离子聚合物制剂通过螯合型药物相互作用影响多替拉韦的药代动力学。

Multivalent cation and polycation polymer preparations influence pharmacokinetics of dolutegravir via chelation-type drug interactions.

机构信息

Division of Pharmacodynamics, Keio University Faculty of Pharmacy, 1-5-30 Shibakoen, Minato-ku, Tokyo, 105-8512, Japan.

Division of Practical Pharmacy, Keio University Faculty of Pharmacy, 1-5-30 Shibakoen, Minato-ku, Tokyo, 105-8512, Japan.

出版信息

Drug Metab Pharmacokinet. 2021 Apr;37:100371. doi: 10.1016/j.dmpk.2020.11.006. Epub 2020 Nov 23.

DOI:10.1016/j.dmpk.2020.11.006
PMID:33556698
Abstract

Dolutegravir (DTG) is an integrase inhibitor, whose gastrointestinal absorption is impaired by the formation of chelates with multivalent metal cation preparations. However, little is known regarding the interactions of DTG with preparations containing other multivalent metal cations or with polycation polymer preparations. This study examined how the pharmacokinetics of DTG are affected by co-administration with Al(OH), LaCO, and the polycation polymers bixalomer (Bxl) and sevelamer (Svl). Prior to oral administration of DTG (5 mg/kg), rats were orally administered Al(OH) (150 or 300 mg/kg), LaCO (50 or 75 mg/kg), Bxl (250 or 500 mg/kg), or Svl (300 or 600 mg/kg). Serum concentrations of DTG were then measured over the next 24 h. Compared to the administration of DTG alone, its co-administration with Al(OH), LaCO, Bxl, and Svl led to reduced serum concentration of DTG, and consequently, a significantly reduced area under the curve. These comparisons also revealed a considerable reduction in the maximum concentration, suggesting that the interactions of these agents with DTG in the intestinal tract inhibit absorption of DTG. The above results demonstrate that Al(OH), LaCO, Bxl, and Svl affect the pharmacokinetics of DTG and indicate the need for caution when combining any of the above preparations with DTG.

摘要

多替拉韦(DTG)是一种整合酶抑制剂,其胃肠道吸收会因与多价金属阳离子制剂形成螯合物而受到损害。然而,对于 DTG 与含有其他多价金属阳离子的制剂或与聚阳离子聚合物制剂的相互作用,人们知之甚少。本研究考察了 DTG 与氢氧化铝、碳酸镧和聚阳离子聚合物比沙可啶(Bxl)和司维拉姆(Svl)同时给药时对 DTG 药代动力学的影响。在口服 DTG(5mg/kg)之前,大鼠口服给予氢氧化铝(150 或 300mg/kg)、碳酸镧(50 或 75mg/kg)、Bxl(250 或 500mg/kg)或 Svl(300 或 600mg/kg)。然后在接下来的 24 小时内测量 DTG 的血清浓度。与单独给予 DTG 相比,同时给予 DTG 与氢氧化铝、碳酸镧、Bxl 和 Svl 导致 DTG 的血清浓度降低,因此 AUC 显著降低。这些比较还表明最大浓度有相当大的降低,表明这些药物在肠道中与 DTG 的相互作用抑制了 DTG 的吸收。上述结果表明,氢氧化铝、碳酸镧、Bxl 和 Svl 影响 DTG 的药代动力学,并表明在将上述任何制剂与 DTG 联合使用时需要谨慎。

相似文献

1
Multivalent cation and polycation polymer preparations influence pharmacokinetics of dolutegravir via chelation-type drug interactions.多价阳离子和聚阳离子聚合物制剂通过螯合型药物相互作用影响多替拉韦的药代动力学。
Drug Metab Pharmacokinet. 2021 Apr;37:100371. doi: 10.1016/j.dmpk.2020.11.006. Epub 2020 Nov 23.
2
Concurrent administration with multivalent metal cation preparations or polycationic polymer preparations inhibits the absorption of raltegravir via its chelation.同时使用多价金属阳离子制剂或多阳离子聚合物制剂会通过螯合作用抑制拉替拉韦的吸收。
J Pharm Pharmacol. 2020 Oct;72(10):1361-1369. doi: 10.1111/jphp.13330. Epub 2020 Jul 13.
3
Enhanced Solubility and Bioavailability of Dolutegravir by Solid Dispersion Method: In Vitro and In Vivo Evaluation-a Potential Approach for HIV Therapy.固体分散体法提高多拉韦林的溶解度和生物利用度:体外与体内评价——一种治疗 HIV 的潜在方法。
AAPS PharmSciTech. 2021 Apr 9;22(3):127. doi: 10.1208/s12249-021-01995-y.
4
Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744.利匹韦林与整合酶抑制剂多替拉韦和 GSK1265744 之间不存在药代动力学相互作用。
Antimicrob Agents Chemother. 2013 Nov;57(11):5472-7. doi: 10.1128/AAC.01235-13. Epub 2013 Aug 26.
5
The effect of veno-arterial extracorporeal oxygenation and nasogastric tube administration on the pharmacokinetic profile of abacavir, lamivudine and dolutegravir: a case report.静脉-动脉体外氧合和鼻胃管给药对阿巴卡韦、拉米夫定和多替拉韦药代动力学特征的影响:一例报告。
Antivir Ther. 2020;25(2):115-119. doi: 10.3851/IMP3355.
6
Effect of prednisone on the pharmacokinetics of the integrase inhibitor dolutegravir.泼尼松对整合酶抑制剂多替拉韦药代动力学的影响。
Antimicrob Agents Chemother. 2013 Sep;57(9):4394-7. doi: 10.1128/AAC.00728-13. Epub 2013 Jul 1.
7
Saliva as a potential matrix for evaluating pharmacologically active dolutegravir concentration in plasma.唾液作为评估血浆中具有药理活性的多替拉韦浓度的潜在基质。
PLoS One. 2021 Feb 18;16(2):e0246994. doi: 10.1371/journal.pone.0246994. eCollection 2021.
8
Assessment of Maternal and Fetal Dolutegravir Exposure by Integrating Ex Vivo Placental Perfusion Data and Physiologically-Based Pharmacokinetic Modeling.整合胎盘体外灌流数据和基于生理的药代动力学模型评估母体和胎儿多替拉韦暴露情况。
Clin Pharmacol Ther. 2020 Jun;107(6):1352-1361. doi: 10.1002/cpt.1748. Epub 2020 Jan 24.
9
ABCG2 Deficiency Does Not Alter Dolutegravir Metabolism and Pharmacokinetics.ABCG2 缺乏不改变多替拉韦的代谢和药代动力学。
J Pharmacol Exp Ther. 2020 Jul;374(1):38-43. doi: 10.1124/jpet.119.264424. Epub 2020 Apr 17.
10
Dolutegravir Inhibition of Matrix Metalloproteinases Affects Mouse Neurodevelopment.多替拉韦抑制基质金属蛋白酶影响小鼠神经发育。
Mol Neurobiol. 2021 Nov;58(11):5703-5721. doi: 10.1007/s12035-021-02508-5. Epub 2021 Aug 14.

引用本文的文献

1
Metal-binding proteins and proteases in RNA viruses: unravelling functional diversity and expanding therapeutic horizons.金属结合蛋白和蛋白酶在 RNA 病毒中的作用:揭示功能多样性并拓展治疗前景。
J Virol. 2023 Dec 21;97(12):e0139923. doi: 10.1128/jvi.01399-23. Epub 2023 Nov 20.
2
Gene-nutrient interactions that impact magnesium homeostasis increase risk for neural tube defects in mice exposed to dolutegravir.影响镁稳态的基因-营养素相互作用会增加暴露于多替拉韦的小鼠发生神经管缺陷的风险。
Front Cell Dev Biol. 2023 Jun 12;11:1175917. doi: 10.3389/fcell.2023.1175917. eCollection 2023.